IMMURON Ltd/S (NASDAQ:IMRN) has been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Brokers have set a twelve-month consensus target price of $20.00 for the company, according to Zacks. Zacks has also assigned IMMURON Ltd/S an industry rank of 103 out of 255 based on the ratings given to related companies.
Several research firms have recently weighed in on IMRN. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of IMMURON Ltd/S in a research note on Wednesday, July 25th. ValuEngine raised IMMURON Ltd/S from a “hold” rating to a “buy” rating in a research note on Wednesday, July 11th. Finally, Zacks Investment Research raised IMMURON Ltd/S from a “sell” rating to a “hold” rating in a research note on Tuesday, June 12th.
IMMURON Ltd/S Company Profile
Immuron Limited, a biopharmaceutical company, focuses on the research and development of polyclonal antibodies for the treatment and prevention of various diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that produces antibodies to treat various diseases, including infectious diseases, cancers, and chronic inflammatory diseases.
Featured Story: What is a put option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IMMURON Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMMURON Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.